Moderna and COVID-19: A Live Case Study Event


Join us for a LinkedIn Live event featuring biotech firm Moderna for a demonstration of Harvard’s effective case-study method presented by Professor Karim Lakhani. Lakhani teaches in the Harvard Business School, specializing in technology management, innovation, digital transformation, and artificial intelligence. Read more about the Moderna case below:

In summer 2020, Stéphane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19. Built from the ground up as a digital organization, Moderna was able to respond to the challenge of developing a vaccine as soon as the gene sequence for the virus was posted on Jan. 11, 2020. As the vaccine enters Phase III clinical trials, Bancel considers several issues: How should Bancel and his team balance the demands of developing a vaccine for a virus creating a global pandemic alongside the other important vaccines and therapies in Moderna’s pipeline? How should Moderna communicate its goals and vision to investors in this unprecedented time? Should Moderna be concerned it will be pegged as “a COVID-19 company”?

Register Now